Search

Your search keyword '"Nanda Aryal"' showing total 4 results
Start Over Author "Nanda Aryal" Database OpenAIRE
4 results on '"Nanda Aryal"'

1. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Author

Fabian Trillsch, Sven Mahner, Beyhan Ataseven, Rebecca Asher, Nanda Aryal, Coraline Dubot, Andrew Clamp, Richard T. Penson, Amit Oza, Amnon Amit, Tomasz Huzarski, Antonio Casado, Giovanni Scambia, Michael Friedlander, Nicoletta Colombo, Keiichi Fujiwara, Gabe S. Sonke, Hannelore Denys, Elizabeth S. Lowe, Chee K. Lee, Eric Pujade-Lauraine, Trillsch, F, Mahner, S, Ataseven, B, Asher, R, Aryal, N, Dubot, C, Clamp, A, Penson, R, Oza, A, Amit, A, Huzarski, T, Casado, A, Scambia, G, Friedlander, M, Colombo, N, Fujiwara, K, Sonke, G, Denys, H, Lowe, E, Lee, C, and Pujade-Lauraine, E

Subjects
Ovarian Neoplasms, Age dependency, Quality of life, BRCA1 Protein, Obstetrics and Gynecology, Carcinoma, Ovarian Epithelial, Piperazines, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Olaparib, PARP inhibitor, Oncology, Ovarian cancer, Child, Preschool, Mutation, Humans, Phthalazines, Female, Neoplasm Recurrence, Local, PARP inhibitors, Aged
Abstract

Background: Olaparib has significantly improved outcome and patient-centered endpoints in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer (PSOC). Specific information on efficacy and safety of olaparib for older patients appears of special interest. Methods: 295 patients from the SOLO2 trial randomly assigned to olaparib or placebo were categorized according to age-cutoff at 65 years. Efficacy, tolerability, and quality of life (QoL) of olaparib relative to placebo within in each age group was analyzed. Results: Baseline characteristics were similar in patients ≥65 years (N = 62;21.0%) compared to patients

Published
2022

2. Corrigendum to 'Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy' [Diab. Res. Clin. Pract. 186 (2022) 109835]

Author

Benjamin N. Rao, Nicola Quinn, Andrzej S. Januszewski, Tunde Peto, Laima Brazionis, Nanda Aryal, Rachel L. O'Connell, Liping Li, Paula Summanen, Russell Scott, Justin O'Day, Anthony C. Keech, and Alicia J. Jenkins

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine, General Medicine
Published
2023

3. Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy

Author

Nicola, Quinn, Andrzej S, Januszewski, Laima, Brazionis, Rachel, O'Connell, Nanda, Aryal, Justin, O'Day, Russell, Scott, Paul, Mitchell, Alicia J, Jenkins, and Anthony C, Keech

Subjects
Diabetic Retinopathy, Diabetes Mellitus, Type 2, Fenofibrate, Venules, Humans, Retinal Vessels
Abstract

Retinal vessel calibre metrics were evaluated at baseline and 2 years in a FIELD substudy (n = 208). Central retinal venule calibre was significantly reduced by fenofibrate and unchanged by placebo. Arteriole metrics did not change. Larger studies relating retinal vessel calibre to future diabetes complications and response to therapy are merited.

Published
2021

4. Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy

Author

Benjamin N. Rao, Nicola Quinn, Andrzej S. Januszewski, Tunde Peto, Laima Brazionis, Nanda Aryal, Rachel L. O'Connell, Liping Li, Paula Summanen, Russell Scott, Justin O'Day, Anthony C. Keech, and Alicia J. Jenkins

Subjects
Glycated Hemoglobin, Male, Diabetic Retinopathy, Endocrinology, Diabetes Mellitus, Type 2, Fenofibrate, Risk Factors, Endocrinology, Diabetes and Metabolism, Internal Medicine, Humans, General Medicine
Abstract

To evaluate the risk algorithm by Aspelund et al. for predicting sight-threatening diabetic retinopathy (STDR) in Type 2 diabetes (T2D), and to develop a new STDR prediction model.The Aspelund et al. algorithm was used to calculate STDR risk from baseline variables in 1012 participants in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) ophthalmological substudy, compared to on-trial STDR status, and receiver operating characteristic analysis performed. Using multivariable logistic regression, traditional risk factors and fenofibrate allocation as STDR predictors were evaluated, with bootstrap-based optimism-adjusted estimates of predictive performance calculated.STDR developed in 28 participants. The Aspelund et al. algorithm predicted STDR at 2- and 5-years with area under the curve (AUC) 0.86 (95% CI 0.77-0.94) and 0.86 (0.81-0.92), respectively. In the second model STDR risk factors were any DR at baseline (OR 24.0 [95% CI 5.53-104]), HbA1c (OR 1.95 [1.43-2.64]) and male sex (OR 4.34 [1.32-14.3]), while fenofibrate (OR 0.13 [0.05-0.38]) was protective. This model had excellent discriminatory ability (AUC = 0.89).The algorithm by Aspelund et al. predicts STDR well in the FIELD ophthalmology substudy. Logistic regression analysis found DR at baseline, male sex, and HbA1c were predictive of STDR and, fenofibrate was protective.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results